The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD

Noel, Janet; Hougen, Ingrid; Sood, Manish M.

doi:10.3389/fneur.2022.823569

Cited by 10 publications

(6 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sodium‐glucose cotransporter 2 (SGLT2) inhibitors have shown improved cognitive function with both short‐term and long‐term usage 46,47 . The benefits of SGLT2 are believed to be an inhibition of the pro‐inflammatory pathway and a reduction in cerebrovascular disease risk 48 . There are limited data regarding cognitive function with meglitinides, α‐glucosidase inhibitors.…”

Section: Diabetes Mellitus and Psci/post‐stroke Dementia (Psd)mentioning

confidence: 99%

See 1 more Smart Citation

Association between diabetes mellitus and post‐stroke cognitive impairment

Lee

Chen

Wang

2022

J of Diabetes Invest

View full text Add to dashboard Cite

Stroke survivors suffer from various physical, emotional, and cognitive impairments. These changes are dynamic and depend on multiple factors, including underlying diseases, baseline brain function and pathology, the site of the stroke and the post‐stroke inflammation, neurogenesis as well as the subsequent remodeling of the neuro‐network. First we review the structural and pathological changes of the brain in stroke survivors with diabetes mellitus, which may lead to post‐stroke cognitive dysfunction. Second, we provide evidence of hyperglycemia, diabetes mellitus, hypoglycemia, and their relationship with post‐stroke cognitive impairment (PSCI) and post‐stroke dementia (PSD). In addition to conventional biomarkers, such as HbA1c, we also provide other novel tools to predict PSCI/PSD, such as glycemic variability, receptor for advanced glycation end products, and gut microbiota. Finally, we attempt to provide some modifying methods for glycemic control, focusing on the prevention of PSCI/PSD.

show abstract

Section: Diabetes Mellitus and Psci/post‐stroke Dementia (Psd)mentioning

confidence: 99%

“…46,47 The benefits of SGLT2 are believed to be an inhibition of the proinflammatory pathway and a reduction in cerebrovascular disease risk. 48 There are limited data regarding cognitive function with meglitinides, a-glucosidase inhibitors. However, the use of insulin is different.…”

Section: Biomarkers For Psci/psdmentioning

confidence: 99%

Association between diabetes mellitus and post‐stroke cognitive impairment

Lee

Chen

Wang

2022

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…Hence, blood pressure regulation is a key strategy for limiting kidney damage and reducing morbidity and mortality in patients with hypertension [31]. Early treatment of CKD and comorbid cardiovascular risk factors and diseases using SGLT2 inhibitors has also been hypothesised to prevent cognitive impairment [32].…”

Section: Importance Of Early Diagnosis and Treatmentmentioning

confidence: 99%

The importance of early diagnosis and intervention in chronic kidney disease: Calls-to-action from nephrologists based mainly in Central/Eastern Europe

Covic,

Säemann,

Filipov

et al. 2024

Kidney Blood Press Res

View full text Add to dashboard Cite

Background Chronic kidney disease (CKD) has a global prevalence of 9.1–13.4%. Comorbidities are abundant and may cause and affect CKD. Cardiovascular disease strongly correlates with CKD, increasing the burden of both diseases. Summary As a group of 15 clinical nephrologists primarily practicing in 12 Central/Eastern European countries, as well as Israel and Kazakhstan, herein we review the significant unmet needs for patients with CKD and recommend several key calls-to-action. Early diagnosis and treatment are imperative to ensure optimal outcomes for patients with CKD, with the potential to greatly reduce both morbidity and mortality. Lack of awareness of CKD, substandard indicators of kidney function, suboptimal screening rates, and geographical disparities in reimbursement often hamper access to effective care. Key Messages Our key calls-to-action to address these unmet needs, thus improving the standard of care for patients with CKD, are: increase disease awareness, such as through education; encourage provision of financial support for patients; develop screening algorithms; revisit primary care physician referral practices; and create epidemiological databases that rectify the paucity of data on early-stage disease. By focusing attention on early detection, diagnosis, and treatment of high-risk and early-stage CKD populations we aim to reduce the burdens, progression, and mortality of CKD.

show abstract

“…Sodium-glucose cotransporter 2 inhibitors (SGLT2i), primarily recognized for their antidiabetic effects, have recently emerged as potential protectors against neuronal cell death and neurotoxic damage [241]. In this context, exploring their multifaceted activities becomes crucial.…”

Section: Preventing Neuronal Cell Death and Neurotoxic Damagementioning

confidence: 99%

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy

Złotek,

Kurowska,

Herbet

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Alzheimer’s is a prevalent, progressive neurodegenerative disease marked by cognitive decline and memory loss. The disease’s development involves various pathomechanisms, including amyloid-beta accumulation, neurofibrillary tangles, oxidative stress, inflammation, and mitochondrial dysfunction. Recent research suggests that antidiabetic drugs may enhance neuronal survival and cognitive function in diabetes. Given the well-documented correlation between diabetes and Alzheimer’s disease and the potential shared mechanisms, this review aimed to comprehensively assess the potential of new-generation anti-diabetic drugs, such as GLP-1 analogs, SGLT-2 inhibitors, and DPP-4 inhibitors, as promising therapeutic approaches for Alzheimer’s disease. This review aims to comprehensively assess the potential therapeutic applications of novel-generation antidiabetic drugs, including GLP-1 analogs, SGLT-2 inhibitors, and DPP-4 inhibitors, in the context of Alzheimer’s disease. In our considered opinion, antidiabetic drugs offer a promising avenue for groundbreaking developments and have the potential to revolutionize the landscape of Alzheimer’s disease treatment.

show abstract

The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD

Cited by 10 publications

References 52 publications

Association between diabetes mellitus and post‐stroke cognitive impairment

Association between diabetes mellitus and post‐stroke cognitive impairment

The importance of early diagnosis and intervention in chronic kidney disease: Calls-to-action from nephrologists based mainly in Central/Eastern Europe

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy

Contact Info

Product

Resources

About